| Objective Raltitrexed is a kind of new generation of aqueous soluble thymidylate synthase inhibitor.We carried out this study to compare the efficacy and adverse reactions of raltitrexed/cisplatin-based concurrent chemoradiotherapy with docetaxe/cisplatin-based concurrent chemoradiotherapy in the treatment of advanced esophageal cancer.METHODS One hundred and four patients with locally advanced esophageal squamous cell carcinoma were randomly divided into the raltitrexed group(n=54)and the docetaxel group(n=50).All patients received chest radiotherapy,using Intensity-modulated radiotherapy(IMRT)or Three-dimensional conformal radiotherapy(3D-CRT).During the course of radiotherapy,chemotherapy with combination of raltitrexed and cisplatin or combination of docetaxel and cisplatin was conducted for 2 cycles.The short-term efficacy and adverse effects were compared between the two groups.RESULTS The objective response rate(RR)and the disease control rate(DCR)were 85.2%94.4%in the raltitrexed group,and 80%and 92%in the docetaxel group,respectively(P =0.485 and 0.708,respectively).The 1-year survival rate was 85.1%in the raltitrexed group and 71.0%in the docetaxel group,with a statistically significant difference(?2=4.181,P=0.041).The median progression-free survival and 1-year progression-free survival were not significantly different between the two groups(?2=2.931,P=0.087).The 1-year local progression-free survival was better in the raltitrexed group than in the docetaxel group(?2=4.063,P=0.044).The main adverse reactions included myelosuppression,gastrointestinal reaction and increased transferase,and were not significantly different between the two groups(P>0.05).Conclusion Raltitrexed/cisplatin-based concurrent chemoradiotherapy was able to improve the 1-year survival rate and local progression-free survival rate of patients with locally advanced esophageal carcinoma.Adverse reactions could be well tolerated. |
PDF Full Text Request